The effects of platelet-activating factor (PAF) and a PAF antagonist (CV-3988) on smoke inhalation injury in an ovine model

Journal of Trauma - Injury, Infection and Critical Care

Volumn 32, Issue 3, 1992, Pages 344-350

  Ikeuchi, Hisashi ^a   Sakano, Tsutomu ^a   Sanchez, Jose ^b   Mason, Arthur D ^b   Pruitt, Basil A ^b  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE; MALONALDEHYDE; PROSTAGLANDIN E2; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR AFFECTING AGENT; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; INHALATION; INJURY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIPID PEROXIDATION; LUNG LAVAGE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SHEEP; SMOKE; THROMBOCYTE COUNT;

ANIMAL; DINOPROSTONE; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; PHOSPHOLIPID ETHERS; PLATELET ACTIVATING FACTOR; PLATELET COUNT; SHEEP; SMOKE INHALATION INJURY; THROMBOXANE B2; TIME FACTORS;

EID: 0026598154     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/00005373-199203000-00012     Document Type: Article

References (27)

1. Camussi G, Pawlowski I, Tetta C, et al: Acute lung inflammation induced in the rabbit by local instillation of l-O-octadecyl-2- acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. Am J Pathol 112:78, 1983
2. Halonen M, Palmer JD, Lohman IC, et al: Differential effects of platelet depletion on the physiologic alterations of IgE anaphylaxis and acetyl glyceryl ether phosphorylcholine infusion in the rabbit. Am Rev Respir Dis 124:416, 1981
3. Pinckard RN, Farr RS, Hanahan DJ: Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J Immunol 123:1847, 1979
4. Shaw JO, Pinckard RN, Ferrigni KS, et al: Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor). J Immunol 127:1250, 1981
5. Wardlaw AJ, Moqbel R, Cromwell O, et al: Platelet activating factor (PAF): A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 78:1701, 1986
6. Wills ED: The effect of inorganic iron on the thiobarbituric acid method for the determination of lipid peroxides. Biochim Biophys Acta 84:475, 1964
7. Yasaka T, Boxer LA, Baehner RL: Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl- phenylalanine (FMLP) and platelet-activating factor (PAF). J Immunol 128:1939, 1982
8. Chang SW, Feddersen CO, Henson PM, et al: Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 79:1498, 1987
9. Duncan SG, Demeter RJ, Toth PD: The effects of a platelet-activating factor antagonist (CV-3988) on endotoxic and hemorrhagic shock in dogs (abstr). Crit Care Med 14:413, 1986
10. Fletcher JR, DiSimone G, Earnest MA, et al: Platelet activating factor (PAF) receptor antagonist, BN52021, improves survival and inhibits prostaglandin release in endotoxemia (abst). J Trauma 28:1085, 1988.
11. Terashita Z, Imura Y, Nishikawa K, et al: Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur J Pharmacol 109:257, 1985
12. Terashita Z, Tsushima S, Yoshioka Y, et al: CV-3988—A specific antagonist of platelet activating factor (PAF). Life Sci 32:1975, 1983
13. Toth PD, Mikulaschek AW: Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat. Circ Shock 20:193, 1986
14. Shimazu T, Yukioka T, Hubbard GB, et al: A dose-responsive model of smoke inhalation injury: Severity-related alteration in cardiopulmonary function. Ann Surg 206:89, 1987
15. Betz SJ, Henson PM: Production and release of platelet-activating factor (PAF); dissociation from degranulation and superoxide production in the human neutrophil. J Immunol 125:2756, 1980
16. Huang YS, Li A, Yang ZC: Effect of smoke inhalation injury on thromboxane levels and platelet counts. Burns Incl Therm Inj 14:440, 1988
17. Niehaus WG, Jr, Samuelsson B: Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 6:126, 1968
18. Wills ED: Lipid peroxide formation in microsomes: General considerations. Biochem J 113:315, 1969
19. Rivkind AI, Siegel JH, Guadalupi P, et al: Sequential patterns of eicosanoid, platelet, and neutrophil interactions in the evolution of the fulminant post-traumatic adult respiratory distress syndrome. Ann Surg 210:355, 1989
20. Chang SW, Fernyak S, Voelkel NF: Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury. Am J Physiol 258:H153, 1990
21. Sharar SR, Heimbach DM, Howard M, et al: Cardiopulmonary responses after spontaneous inhalation of Douglas fir smoke in goats. J Trauma 28:164, 1988
22. Huber CT, Edwards HH, Morrison M: The effect of lactoperoxi-dase-catalyzed iodination on the integrity of mitochondrial membranes. Arch Biochem Biophys 168:463, 1975
23. Demling RH, Lalonde C, Ryan P, et al: Endotoxemia produces an increase in arterial but not venous lipid peroxides in sheep. J Appl Physiol 64:592, 1988
24. Kjellstrom BT, Risberg B: High dose corticosteroids and cell-cell interactions; Acta Chir Scand [Suppl] 526:37, 1985
25. Traber DL, Herndon DN, Stein MD, et al: The pulmonary lesion of smoke inhalation in an ovine model. Circ Shock 18:311, 1986
26. Ikeuchi H, Sakano T, Mason AD, Jr, et al: The effect of platelet-activating factor (PAF) and a PAF antagonist (CV-3988) on smoke inhalation injury using an ovine model—Physiological change (abstr). Proceedings of the American Burn Association 22nd Annual Meeting, 1990, p 22
27. Demling RH, LaLonde C, Jin LJ, et al: Endotoxemia causes increased lung tissue lipid peroxidation in unanesthetized sheep. J Appl Physiol 60:2094, 1986